Melanoma is widely considered the worst skin cancer, responsible for the vast majority of skin cancer deaths despite accounting for a small fraction of cases. But it’s not the only aggressive form. Merkel cell carcinoma, a rarer cancer, is actually more lethal on a case-by-case basis, and cutaneous angiosarcoma carries one of the lowest survival rates of any skin malignancy.
Which one is “worst” depends on what you mean. Melanoma kills the most people in total. Merkel cell carcinoma is more likely to kill any individual who gets it. And angiosarcoma has the bleakest overall prognosis. Here’s what makes each of them dangerous and how they compare.
Melanoma: The Most Common Killer
Melanoma develops in the cells that give skin its color. It’s the skin cancer most people fear, and for good reason: it spreads aggressively once it gets past the early stages, and it causes more deaths than all other skin cancers combined. About 100,000 Americans are diagnosed with invasive melanoma each year, and roughly 8,000 die from it annually.
The survival picture depends almost entirely on when it’s caught. According to SEER data from 2016 to 2022, the five-year survival rate for melanoma that hasn’t spread beyond the original site is 100%. Once it reaches nearby lymph nodes, that drops to 76%. If it has metastasized to distant organs, the five-year survival rate falls to 34%.
That steep drop happens because melanoma cells are remarkably good at surviving the journey through the body. Research from the National Cancer Institute found that melanoma cells traveling through lymph nodes absorb a fatty acid called oleic acid, which gets incorporated into their outer membranes. This protects them from a type of cell death called ferroptosis, where oxidative stress would normally destroy the membrane and kill the cell. As one researcher put it, the melanoma cells “load up on oleic acid in the lymph, and then once they go into the blood, they’re bulletproof.” Patients whose tumors spread more efficiently also tend to have higher levels of a transporter molecule that helps cells manage oxidative stress, giving them an additional survival advantage.
The good news is that immunotherapy has dramatically changed outcomes for advanced melanoma. A phase I trial combining two immune checkpoint drugs showed tumor shrinkage in 57% of patients with advanced melanoma, and 25% had a complete response, meaning the cancer disappeared entirely. These numbers would have been unimaginable 15 years ago.
Merkel Cell Carcinoma: More Lethal Per Case
Merkel cell carcinoma (MCC) is far rarer than melanoma, with only about 3,000 cases diagnosed per year in the United States. But it is, statistically, the more dangerous diagnosis. A comparative study covering 2000 to 2021 found that MCC patients were more than twice as likely to die from their cancer compared to melanoma patients, with a hazard ratio of 2.33.
What makes MCC so dangerous is speed. It tends to grow quickly and metastasize at an early stage. It typically appears on sun-exposed skin as a single, fast-growing, painless lump that’s often flesh-colored, red, or bluish-purple. Because it doesn’t look like what most people picture when they think of skin cancer, it’s frequently mistaken for a cyst or insect bite. That delay in recognition gives it time to spread.
MCC is linked to a virus called Merkel cell polyomavirus in about 80% of cases, and it occurs most often in older adults and people with weakened immune systems. The five-year survival rate across all stages hovers around 60 to 65%, but for distant-stage disease, it drops well below that. Immunotherapy has improved treatment options significantly, but MCC remains harder to treat than melanoma once it has spread.
Angiosarcoma: The Rarest and Most Aggressive
Cutaneous angiosarcoma is a cancer of the blood vessel lining that occurs in the skin, most commonly on the scalp and face of older adults. It’s exceptionally rare, but it carries the worst prognosis of any skin cancer. The median survival after diagnosis ranges from just 15 to 24 months, and the five-year survival rate sits between 12% and 33%.
Part of the problem is that angiosarcoma is hard to recognize. It can look like a bruise, a rash, or a non-healing wound. Delayed diagnosis is common, and by the time it’s identified, the cancer has often already extended locally or spread to the lungs, liver, or bone. Even with aggressive treatment, local recurrence and metastasis are frequent. Death can result from either the cancer spreading to distant organs or from its relentless local growth destroying surrounding tissue.
Why Some Melanomas Are Harder to Catch
Most people learn the “ABCDE” rule for spotting melanoma: look for asymmetry, border irregularity, color variation, diameter larger than a pencil eraser, and evolution over time. But a subset called amelanotic melanoma doesn’t follow these rules. It produces little to no pigment, so instead of appearing as a dark or multicolored mole, it’s usually pink or light brown. MD Anderson Cancer Center notes that this subtle difference makes it challenging for patients to identify on their own. Amelanotic melanomas are still somewhat distinct from the surrounding skin, but they don’t trigger the alarm bells that a dark, irregular mole would. This leads to later diagnoses and, predictably, worse outcomes.
If you have a spot on your skin that is growing, changing, or simply doesn’t heal within a few weeks, the color alone is not a reliable way to rule out melanoma.
How the Three Compare
- Total deaths per year: Melanoma kills far more people because it’s far more common. MCC and angiosarcoma are rare enough that their total death counts are much lower, even though each individual case is more dangerous.
- Survival if caught early: Melanoma has a near-perfect survival rate when localized. MCC has good but lower early-stage survival. Angiosarcoma has poor survival even with early treatment.
- Speed of spread: MCC metastasizes earliest relative to its size. Melanoma spreads efficiently once it reaches a certain depth. Angiosarcoma tends to recur locally and metastasize to the lungs.
- Treatment response: Melanoma responds best to modern immunotherapy. MCC also responds to immunotherapy but less reliably. Angiosarcoma has the fewest effective treatment options.
If you’re asking which skin cancer you should most worry about, the practical answer is melanoma, because it’s by far the most likely to affect you or someone you know. But if you’re asking which skin cancer is most lethal once you have it, angiosarcoma carries the worst odds, followed by Merkel cell carcinoma. The single most important factor across all three is how early they’re found. A melanoma caught before it spreads is nearly 100% survivable. The same cancer caught after it reaches distant organs drops to a one-in-three chance of surviving five years. That gap is larger than the difference between any two types of skin cancer.